2026
/
04
/
15
JIC Venture Growth Investments Co., Ltd. (VGI), through JIC Venture Growth Fund 2, has invested in Alloy Therapeutics, Inc. (“Alloy”).
Alloy is a biotech infrastructure company providing AI-enabled platforms and integrated services across multiple modalities, including antibodies, genetic medicines, and cell therapies, to more than 200 partners. To date, Alloy has supported the creation of over 100 therapeutic programs, of which 22 have advanced into clinical development. Building on its foundation in drug discovery, the company has expanded its capabilities across the full drug development lifecycle, including pharmacology, preclinical and clinical development support, as well as biologics manufacturing. Alloy enables a more efficient path from discovery to the clinic—reducing costs, shortening timelines, and increasing the probability of success. The company ultimately aims to enable the development of therapies for all diseases and to improve the accessibility and affordability of medicines.
Alloy is also expanding its presence in Japan, and its platform is expected to connect Japanese research institutions and companies to the global drug discovery ecosystem. In particular, Alloy is well positioned to support innovation emerging from Japanese startups and academia, while fostering globally competitive talent, thereby contributing to the strengthening of Japan’s life sciences ecosystem. Through this investment, VGI aims to enhance Japan’s global competitiveness in life sciences and accelerate innovation.
